CellaVision AB ( (SE:CEVI) ) has shared an announcement.
At its Annual General Meeting, CellaVision AB resolved to adopt the financial statements for 2024, approve a dividend of SEK 2.50 per share, and re-elect key board members, including Mikael Worning as Chairman. The AGM also authorized the board to repurchase and transfer shares, aiming to optimize capital structure and enhance shareholder value, while facilitating working capital procurement and ownership base expansion.
More about CellaVision AB
CellaVision is a global medical technology company specializing in the development and sale of advanced systems for routine blood and body fluid analysis, crucial for diagnosing infections and serious cancers. The company leverages expertise in sample preparation, image analysis, AI, and automated microscopy, distributing its products through global partners and local market support organizations across more than 40 countries. With a sales target of 15% annual growth, CellaVision reported SEK 723 million in sales for 2024 and is listed on the Nasdaq Stockholm, Mid Cap list.
Average Trading Volume: 27,700
Current Market Cap: SEK4.95B
See more data about CEVI stock on TipRanks’ Stock Analysis page.